^
Association details:
| Biomarker: | BRAF mutation + MSI-L/dMMR |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | AiRuiKa (camrelizumab) (PD1 inhibitor) + SHR7390 (MEK1 inhibitor, MEK2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A phase I study of SHR7390 plus camrelizumab in advanced/metastatic colorectal cancer
Published date:
05/19/2021
Excerpt:
pts with treatment-refractory advanced or metastatic CRC were enrolled to receive SHR7390...plus camrelizumab...Five pts (23%) achieved partial response (0.125 and 0.25 mg cohorts, n = 1 each; 0.5 mg cohort, n =3), including one out of three pts with MSS/MSI-L &BRAF mutant tumors (response lasting 13 months), one out of 15 pts with MSS/MSI-L &BRAF wild type tumors (response lasting 8 months), and all three pts with MSI-H tumors (responses lasting 31, 11, and 10 months, respectively). Three pts with MSS/MSI-L achieved stable disease, and the overall disease control rate reached 36%.
DOI:
10.1200/JCO.2021.39.15_suppl.e15553
Trial ID:
